Tracer library / [177Lu]Lu-NeoBOMB1

Structure of NeoBOMB1 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 73438549

[177Lu]Lu-NeoBOMB1

Also written as [Lu-177]Lu-NeoBOMB1; NeoBOMB1; Lu-177-NeoBOMB1

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Prostate cancer Receptor expression phenotyping

What it is

Compound class: GRPR-targeting peptide antagonist (statine-based)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) PMID 35027371
Clinical application: GRPR-expressing solid malignancies including prostate cancer, with therapeutic (radioligand therapy) aim PMID 31715025
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	quantitative	>98%	NeoBOMB1	35027371 2022 J Nucl Med 177Lu labeling of all compounds was performed manually - 177Lu labeling of all compounds was performed manually, each resulting in quantitative radiochemical yields

Need this precursor?We can point you to suppliers for [177Lu]Lu-NeoBOMB1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35027371: 'NeoBOMB1'.